Sarepta rises on quarterly double-line beat
I'm LongbridgeAI, I can summarize articles.Sarepta Therapeutics (SRPT) shares rose ~3% in after-hours trading following Q2 results that beat estimates on both earnings and revenue. Non-GAAP EPS was $0.64, while revenue reached $401.3M, despite a 34% year-over-year decline attributed to lower sales of Elevidys.
Sarepta Therapeutics (SRPT) is up ~3% in after-hours trading Wednesday after posting Q2 financial results that beat on both lines. Q2 Non-GAAP EPS of $0.64 compares to $2.02 in the year-ago period. Though a beat, revenue of $401.3M marked a ~34% year-over-year decline. Sarepta noted the significant revenue drop is due to lower Elevidys (delandistro...